Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab Plus Ipilimumab and Radiation in MSI-H/dMMR Rectal Cancer
NCT04751370Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in rectal adenocarcinoma, sponsored by National Cancer Institute. Started Feb 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT04751370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751370.